Abstract：Objective: To analyze the diagnostic values of miR-133a and miR-208a in myocardial injury after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS). Methods: 83 patients with ACS who underwent PCI in Handan First Hospital from June 2017 to January 2019 were divided into 41 patients with myocardial injury group and 42 patients with non-myocardial injury group according to the myocardial injury after PCI. Real-time fluorescence quantitative polymerase chain reaction (RT-PCR) was used to detect the levels of serum miR-133a and miR-208a, serum troponin I (cTnI) levels were measured by chemiluminescence immunoassay, Pearson correlation method was used to analyze the correlations between levels of serum miR-133a and miR-208a with cTnI, subject operating characteristic curve (ROC) was used to evaluate the diagnostic value of miR-133a and miR-208a in patients with myocardial injury after PCI. Results: The levels of serum cTnI and the relative expressions of miR-133a and miR-208a in myocardial injury group were significantly higher than those in non-myocardial injury group (P < 0.05); the relative expressions of miR-133a and miR-208a in serum of patients were positively correlated with the level of cTnI (r = 0.741, 0.770, P < 0.001); the areas under ROC curve (AUC) of miR-133a and miR-208a in diagnosing myocardial injury after PCI in ACS patients were 0.809 (95%CI was 0.825-0.961) and 0.853 (95%CI was 0.890-0.990), respectively, the diagnostic thresholds were 0.95 and 0.31, the sensitivity was 93.60% and 95.12%, the specificity was 73.80% and 83.33%, respectively. Conclusion: MiR-133a and miR-208a have good diagnostic sensitivities and specificities for myocardial injury after PCI in ACS patients. They are effective biomarkers of myocardial injury in ACS patients after PCI.
[1] 杨丽霞,郭瑞威.《中国经皮冠状动脉介入治疗指南(2016)》指导急性冠状动脉综合征的临床实践[J].中国介入心脏病学杂志,2016,24(12):714~717. [2] 徐帅,赵翠萍.经皮冠状动脉介入术后相关心肌损伤及前列地尔在其治疗中的研究进展[J].中华老年多器官疾病杂志,2017,16(6):473~476. [3] Shimonaga T, Kurisu S, Watanabe N, et al. Myocardial injury after percutaneous coronary intervention for in-stent restenosis versus de novo stenosis[J]. Internal Med, 2015, 54(18):2299~2305. [4] 李卉卉.经皮冠状动脉介入术相关的心肌损伤及其研究进展[J].心血管病学进展,2017,38(2):151~155. [5] Wu J, Song J, Wang C, et al. Identification of serum microRNAs for cardiovascular risk stratification in dyslipidemia subjects[J]. Int Cardiol, 2014, 172(1):232~234. [6] Arslan F, Bongartz L, Berg JMT, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: comments from the Dutch ACS working group[J]. Neth Heart, 2018, 9(26):417~421. [7] Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction[J]. Circulation, 2012, 126(16):2020~2035. [8] 刘利峰,赵蓓,时全星,等.择期PCI术后肌钙蛋白升高的临床指导意义[J].中国急救复苏与灾害医学杂志,2015,10(2):122~124. [9] Wang E, Nie Y, Zhao Q, et al. Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation[J].Cardiothorac Surg, 2013, 8(1):165. [10] 吴嘉,宋佳希,刘婷,等.急性冠状动脉综合征和稳定性冠状动脉疾病患者血清miR-133a水平变化的初步探讨[J].中华检验医学杂志,2015,38(10):686~690. [11] 刘新秀,葛智儒,赵汉君.血清miR-208a在急性心肌梗死早期及急诊PCI前后表达的研究[J].中国循证心血管医学杂志,2016,8(6):718~720. [12] Li AY, Yang Q, Yang K. miR-133a mediates the hypoxia-induced apoptosis by inhibiting TAGLN2 expression in cardiac myocytes[J]. Mol Cell Biochem, 2015, 400(1-2):173~181. [13] Zhang S, Zhang R, Wu F, et al. MicroRNA-208a regulates H9c2 cells simulated ischemia-reperfusion myocardial injury via targeting CHD9 through notch/NF-kappa B signal pathways[J]. Int Heart, 2018, 59(3):580~588.
2019, Vol. 25 
冀公网安备13080202000677号